SEC Company Response from Phio Pharmaceuticals Corp. (PHIO) (CIK 0001533040) (PHIO) — Feb 7, 2020

Phio Pharmaceuticals Corp. (PHIO) (CIK 0001533040)
Date: Feb. 7, 2020 · CIK: 0001533040 · Accession: 0001683168-20-000392

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-234032

Date

February 7, 2020

Author

H.C. WAINWRIGHT & CO., LLC

Form

CORRESP

Company

Phio Pharmaceuticals Corp. (PHIO) (CIK 0001533040)

Letter

Re: Phio Pharmaceuticals Corp.

February 7, 2020

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Registration Statement on Form S-1 (Registration No. 333-234032)

Concurrence in Acceleration Request

Ladies and Gentlemen:

H.C. Wainwright & Co., LLC (“Wainwright”), as underwriter for the referenced offering, hereby concurs in the request by Phio Pharmaceuticals Corp. that the effective date of the above-referenced registration statement be accelerated to 9:00 a.m. (Eastern Time), or as soon as practicable thereafter, on February 11, 2020 pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is aware of its obligations under the Securities Act in connection with this offering.

Very truly yours,
H.C. WAINWRIGHT & CO., LLC

Show Raw Text

CORRESP
1
filename1.htm

February 7, 2020

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 Re: Phio
Pharmaceuticals Corp.

    Registration
Statement on Form S-1 (Registration No. 333-234032)

    Concurrence
in Acceleration Request

Ladies and Gentlemen:

H.C. Wainwright &
Co., LLC (“Wainwright”), as underwriter for the referenced offering, hereby concurs in the request by Phio Pharmaceuticals
Corp. that the effective date of the above-referenced registration statement be accelerated to 9:00 a.m. (Eastern Time),
or as soon as practicable thereafter, on February 11, 2020 pursuant to Rule 461 under the Securities Act. Wainwright affirms that
it is aware of its obligations under the Securities Act in connection with this offering.

    Very truly yours,

    H.C. WAINWRIGHT & CO., LLC

    By:
    /s/
Edward D. Silvera

    Name:
    Edward D. Silvera
 Title: Chief Operating Officer

SecProbe.io